Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2012

Vertex Tests Oral HCV Combos with Janssen and GSK

  • Vertex Pharmaceuticals announced separate non-exclusive collaborations with Janssen Pharmaceuticals, and with GlaxoSmithKline, to evaluate its HCV drug candidate VX-135, in Phase II studies in combination with Janssen’s Phase III-stage protease inhibitor simeprevir (TMC435), and with GSK’s investigational NS5A inhibitor GSK2336805.

    VX-135 is a uridine nucleotide analogue HCV polymerase inhibitor prodrug that acts on the NS5B polymerase to block HCV replication. The firm is already on track to start all-oral Phase II trials evaluating the drug in combination with ribavirin, and with telaprevir, within the next few months. FDA approved Vertex’ oral HCV drug Incivek™ (telaprivir) back in May 2011.

    Under terms of the deal with Janssen, a Phase II proof-of-concept study is expected to start during early 2013 to test the safety, tolerability, and viral cure rates of 12 weeks of therapy using oral VX-135 combined with oral simeprevir, either with or without ribavirin, in treatment-naive patients with chronic, non-cirrhotic genotype 1 HCV. Vertex and Janssen will share associated costs.

    The collaboration with GSK will involve a similarly designed Phase II proof-of-concept study evaluating VX-135 in combination with GSK’s GSK2336805. The trial will be conducted by Vertex in the U.S., and costs will be shared with GSK.

    Simeprevir is a once-daily HCV protease inhibitor in late-stage development by Janssen R&D and Medivir. The drug is also being evaluated in Phase III trials as combination therapy with PEGinterferon/ribavirin, and in Phase II interferon-free studies in combination with direct-acting antiviral agents with and without ribavirin. 

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »